Trendlines Group, which is listed in the SGX Catalist, has exited BioSight via a trade sale to Arkin Bio Ventures Limited Partnership for a cash consideration of $1.3 million ($1 million post-tax).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
